CMS Outlines 3 New Drug Pricing Models Targeting Wide Scope of Therapies

Targeting everyday chronic conditions to rare diseases that require costly treatments, CMS Tuesday announced an intent to test 3 new models in an effort to lower drug prices and widen access across Medicare Part D, Medicare Part B, and Medicaid.